Combination of Pyrosequencing® and Sanger sequencing reveals alleged novel mutation in exon 18 of EGFR

Personalized Medicine

Volumn 10, Issue 2, 2013, Pages 201-209

  Schildgen, Verena ^a   Schulz, Carolin ^a   Lüsebrink, Jessica ^a   Tillmann, Ramona Liza ^a   Engel Riedel, Walburga ^b   Stoelben, Erich ^b   Schildgen, Oliver ^a   Brockmann, Michael ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b KLINIKEN DER STADT KÖLN GGMBH   (Germany)

Author keywords

EGFR; mutation analysis; NSCLC; Pyrosequencing ; Sanger sequencing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EXON; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PYROSEQUENCING; SANGER SEQUENCING;

EID: 84874612566     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.122     Document Type: Article

References (31)

1. Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 340, b5569 (2010).
2. Pathak AK, Bhutani M, Mohan A, Guleria R, Bal S, Kochupillai V. Non small cell lung cancer (NSCLC): current status and future prospects. Indian J. Chest Dis. Allied Sci. 46(3), 191-203 (2004).
3. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumors. Eur. Respir. J. 18(6), 1059-1068 (2001).
4. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169-181 (2007).
5. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small lung cancer. Br. J. Cancer 55(5), 513-516 (1987).
6. Haeder M, Rotsch M, Bepler G et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res. 48(5), 1132-1136 (1988).
7. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21(20), 3798-3807 (2003).
8. Press MF, Lenz HJ. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67(14), 2045-2075 (2007).
9. Jynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
10. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
11. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
12. Mok TS, Wu Y-L, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
13. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2(3), e73 (2005).
14. Yun CH, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by inceasing the affitnity for ATP. Proc. Natl Acad. Sci. USA 105(6), 2070-2075 (2008).
15. Rosell R, Molina MA, Costa C et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Cancer Res. 17(5), 1160-1168 (2011).
16. Rosell R, Molina MA, Serrano MJ. EGFR mutations in circulating tumor DNA. Lancet Oncol. 13, 971-973 (2012).
17. Mok TS, Wu Y-L, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
18. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010).
19. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11, 121-128 (2010).
20. Schildgen V, Lüsebrink J, Appel JD et al. Identification of uncommon PIK3CA mutations in lung cancer by using Pyrosequencing. Diagn. Mol. Pathol. doi:10.1097/PDM.0b013e31825f5f93 (2013) (Epub ahead of print).
21. Schildgen V, Lüsebrink J, Schultz C et al. Identification of novel mutations in EGFR exon 18. Der Pathologe 32(Suppl. 1), S98 (2011) (Abstract Sa-085).
22. Yunxia Z, Jun C, Guanshan Z, Yachao L, Xueke Z, Jin L. Mutations in epidermal growth factor receptor and K-ras in chinese patients with colorectal cancer. BMC Med. Genet. 11, 34 (2010).
23. Zhang XT, Li LY, Mu XL et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann. Oncol. 16(8), 1334-1342 (2005).
24. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4(10), 1681-1689 (2007).
25. Kotoula V, Charamlambous E, Biesmans B et al. Targeted KRAS mutation assessment on patient tumor histological material in real time diagnostics. PLoS ONE 4(11), e7746 (2009).
26. Ronaghi M, Karamohamed S, Petterson B, Uhlén M, Nyrén P. Real-time sequencing using detection of pyrophosphate release. Anal Biochem. 242(1), 84-89 (1996).
27. Ronaghi M, Uhlén M, Nyrén P. A sequencing method based on real-time pyrophosphate. Science 281(5375), 363, 365 (1998).
28. Willmore-Payne C, Holden JA, Wittwer CT, Layfield JL. The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer. J. Biomol. Tech. 19(3), 217-224 (2008).
29. Ogino S, Kawasaki T, Brahmandam M et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J. Mol. Diagn. 7(3), 413-421 (2005).
30. Lindström A, Odeberg J, Albert J. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J. Clin. Microbiol. 42(10), 4788-4795 (2004).
31. Schildgen V, Lochi V, Lüsebrink J, Brockmann M, Schildgen O. Epidemiology of EML4-ALK translocations in a small, German non-small-cell lung cancer patient cohort. Per. Med. 9(8), 801-803 (2012).